Expert Interview
A Second Opinion: Discussing the standard of care and/or the potential of semaglutide to treat chronic kidney disease and Novo Nordisk's decision to stop their semaglutide kidney outcomes trial, FLOW
Ticker(s): NVODr. Beatrice Goilav - MD (Montefiore)
- Medical Director, Pediatric Nephrology at Montefiore Health System, Inc., Associate Professor of Pediatrics at the Albert Einstein College of Medicine & Visiting Assistant Professor at Rockefeller University.
- Currently treats 400 patients with chronic kidney disease.
- Familiar with the FLOW trail, regarding the effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
